Share on StockTwits

Equities researchers at Sterne Agee initiated coverage on shares of Hospira (NYSE:HSP) in a research report issued on Wednesday, reports. The firm set a “neutral” rating and a $39.00 price target on the stock. Sterne Agee’s price target points to a potential downside of 10.09% from the company’s current price.

A number of other analysts have also recently weighed in on HSP. Analysts at Zacks reiterated a “neutral” rating on shares of Hospira in a research note on Tuesday, April 8th. They now have a $45.00 price target on the stock. Separately, analysts at EVA Dimensions upgraded shares of Hospira from an “underweight” rating to a “hold” rating in a research note on Thursday, March 6th. Finally, analysts at Guggenheim raised their price target on shares of Hospira from $49.00 to $53.00 in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $43.14.

Shares of Hospira (NYSE:HSP) opened at 43.43 on Wednesday. Hospira has a 1-year low of $30.86 and a 1-year high of $45.24. The stock has a 50-day moving average of $42.88 and a 200-day moving average of $41.68. The company’s market cap is $7.229 billion.

Hospira (NYSE:HSP) last announced its earnings results on Wednesday, February 12th. The company reported $0.51 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.50 by $0.01. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the company posted $0.55 earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis. On average, analysts predict that Hospira will post $2.12 earnings per share for the current fiscal year.

Hospira, Inc (NYSE:HSP) is a provider of injectable drugs and infusion technologies.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.